Nielsen H J, Nielsen H, Jensen S, Moesgaard F
Department of Surgical Gastroenterology, Hvidovre University Hospital, Denmark.
Arch Surg. 1994 Mar;129(3):309-15. doi: 10.1001/archsurg.1994.01420270087019.
The histamine H2-receptor antagonist ranitidine hydrochloride has been shown to improve trauma-, blood transfusion-, and sepsis-induced immunosuppression.
To evaluate the effect of ranitidine on postoperative impairment in monocyte and neutrophil function.
Twenty-four patients undergoing major elective abdominal surgery were randomized to receive adjuvant treatment with ranitidine hydrochloride (100 mg) administered twice a day intravenously from skin incision for 4 days, followed by oral ranitidine hydrochloride (150 mg) administered twice a day for 5 days (n = 11), or no adjuvant treatment (n = 13). Blood monocyte and neutrophil chemotaxis and chemiluminescence were analyzed before the operation and on postoperative days 1, 3, and 9.
Monocyte chemotaxis to C5a in the 13 control patients was significantly decreased on day 1 compared with day 0. Chemotaxis in the 11 ranitidine-treated patients increased significantly from day 0 to day 1 (P < .01 between groups). Neutrophil chemiluminescence to zymosan and N-f-methionyl-leucyl-phenylalanine was significantly increased in control patients on day 1 compared with day 0 (P < .05), while ranitidine reduced chemiluminescence to zymosan insignificantly on day 1 (P < .07 between groups). Five of the 13 control patients developed postoperative infectious complications, which were related to decreased monocyte chemotaxis to C5a and increased neutrophil chemiluminescence to zymosan, compared with noninfected patients. A significant difference (P < .05) in chemiluminescence to zymosan between infected and noninfected control patients was observed on day 3 before clinical signs of infectious disease could be detected. There were no infectious complications in ranitidine-treated patients.
These results support previous studies on the effect of ranitidine to improve postoperative immunosuppression.
已证明组胺H2受体拮抗剂盐酸雷尼替丁可改善创伤、输血和脓毒症诱导的免疫抑制。
评估雷尼替丁对术后单核细胞和中性粒细胞功能损害的影响。
24例行择期腹部大手术的患者被随机分为两组,一组接受辅助治疗,从皮肤切口开始静脉注射盐酸雷尼替丁(100mg),每日2次,共4天,随后口服盐酸雷尼替丁(150mg),每日2次,共5天(n = 11);另一组不接受辅助治疗(n = 13)。分别于手术前及术后第1、3和9天分析血液单核细胞和中性粒细胞趋化性及化学发光。
13例对照患者中,单核细胞对C5a的趋化性在第1天较第0天显著降低。11例接受雷尼替丁治疗的患者中,趋化性从第0天到第1天显著增加(两组间P <.01)。对照患者中性粒细胞对酵母聚糖和N - 甲酰 - 甲硫氨酰 - 亮氨酰 - 苯丙氨酸的化学发光在第1天较第0天显著增加(P <.05),而雷尼替丁在第1天对酵母聚糖的化学发光降低不显著(两组间P <.07)。13例对照患者中有5例发生术后感染并发症,与未感染患者相比,这与单核细胞对C5a趋化性降低及中性粒细胞对酵母聚糖化学发光增加有关。在感染性疾病临床体征出现前第3天,感染和未感染对照患者对酵母聚糖的化学发光存在显著差异(P <.05)。接受雷尼替丁治疗的患者未发生感染并发症。
这些结果支持先前关于雷尼替丁改善术后免疫抑制作用的研究。